Blue Path Capital Management, LLC Gilead Sciences, Inc. Transaction History
Blue Path Capital Management, LLC
- $143 Billion
- Q2 2024
A detailed history of Blue Path Capital Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Blue Path Capital Management, LLC holds 10,300 shares of GILD stock, worth $810,816. This represents 0.5% of its overall portfolio holdings.
Number of Shares
10,300
Previous 7,340
40.33%
Holding current value
$810,816
Previous $538 Million
31.44%
% of portfolio
0.5%
Previous 0.41%
Shares
4 transactions
Others Institutions Holding GILD
# of Institutions
1,879Shares Held
1.02BCall Options Held
12MPut Options Held
8.96M-
Black Rock Inc. New York, NY121MShares$9.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$9.07 Billion0.15% of portfolio
-
Capital World Investors Los Angeles, CA76.2MShares$6 Billion0.88% of portfolio
-
Capital Research Global Investors Los Angeles, CA60.4MShares$4.76 Billion0.94% of portfolio
-
State Street Corp Boston, MA59.3MShares$4.67 Billion0.18% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $98.7B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...